Study guide

9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

Key Takeaways Explain This Topic AI

Methylene blue 1 to 2 mg/kg IV over 5 minutes treats symptomatic methemoglobinemia, but it carries a boxed warning for serotonin syndrome and fails in G6PD deficiency.

Isoniazid seizures need pyridoxine 1 g IV per gram ingested, or 5 g IV when the amount is unknown, together with a benzodiazepine.

Octreotide 50 to 100 mcg SC or IV every 6 to 8 hours in adults stops sulfonylurea-driven insulin release and prevents rebound hypoglycemia after dextrose.

L-carnitine 100 mg/kg IV (maximum 6 g) is given for valproate-induced hyperammonemia or hepatotoxicity, and EXTRIP recommends dialysis above a valproate concentration of 1,300 mg/L.

Plain lidocaine is commonly limited to 4.5 mg/kg (300 mg) and lidocaine with epinephrine to 7 mg/kg (500 mg); local anesthetic toxicity is treated with 20% lipid emulsion.

Last updated: October 2026

9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

Note

Exam scope: 2025 outline subtopic 2B13 (Pharmacotherapy for Toxicology) and 2C6 (Adverse Drug Events). These antidotes are commonly tested as dose calculations and as "which antidote fits this mechanism" questions.

  • Methemoglobinemia and Methylene Blue
  • Mechanism and Causes

Methemoglobin forms when the iron in hemoglobin is oxidized from the ferrous (Fe2+) to the ferric (Fe3+) state. Ferric heme cannot carry oxygen, and the remaining heme groups hold oxygen more tightly, shifting the dissociation curve to the left. Normal red cells keep methemoglobin near 1% using NADH-dependent cytochrome b5 reductase.

Common oxidizing causes in emergency practice:

Topical anesthetics , especially benzocaine sprays and gels; FDA warns against benzocaine teething products in children under 2 years.

Dapsone , whose hydroxylamine metabolite causes prolonged, recurrent methemoglobinemia.

Nitrites and nitrates : inhaled alkyl nitrites ("poppers") and nitrate-contaminated well water used for infant formula.

Phenazopyridine, primaquine, rasburicase (in G6PD deficiency) and aniline dyes.

Recognition

Suspect methemoglobinemia when cyanosis does not improve with oxygen, blood looks chocolate-brown, and pulse oximetry stays near 85% regardless of the arterial oxygen tension. This difference between the pulse oximetry reading and the calculated saturation is the "saturation gap." Co-oximetry confirms the diagnosis.

  • Methemoglobin level Typical findings in an otherwise healthy patient
  • 10 to 20% Cyanosis, often few symptoms
  • 20 to 30% Anxiety, headache, tachycardia, lightheadedness
  • 30 to 50% Fatigue, confusion, tachypnea, dizziness
  • 50 to 70% Coma, seizures, dysrhythmias, acidosis
  • Above 70% Often fatal

Anemia, coronary disease or lung disease make patients symptomatic at lower levels.

Methylene Blue

Indication: symptoms of hypoxia, or a methemoglobin level above about 20 to 30% even without symptoms.

Dose: 1 to 2 mg/kg IV over 5 minutes ; repeat 1 mg/kg after about 1 hour if the level or symptoms persist. Cumulative doses above about 7 mg/kg can themselves cause hemolysis and methemoglobinemia.

Mechanism: NADPH-methemoglobin reductase converts methylene blue to leucomethylene blue, which reduces methemoglobin back to hemoglobin. The NADPH comes from the G6PD pathway.

Warning

Methylene blue carries a boxed warning for serotonin syndrome with serotonergic drugs because it is a potent MAO-A inhibitor. It also fails and may cause hemolysis in G6PD deficiency . Alternatives include exchange transfusion, high-dose ascorbic acid and hyperbaric oxygen. Methylene blue also falsely lowers pulse oximetry readings for a short time.

With dapsone, the long half-life causes rebound, so monitor co-oximetry and consider multiple-dose activated charcoal.

Isoniazid: Pyridoxine Is the Antidote

Isoniazid (INH) depletes pyridoxal 5'-phosphate, the cofactor for glutamic acid decarboxylase. GABA synthesis falls, and the result is the classic triad of:

  • Seizures that do not respond to benzodiazepines alone
  • Anion-gap metabolic acidosis (lactate from seizures and impaired lactate metabolism)
  • Coma

Ingestions above about 20 mg/kg can be toxic, and seizures become likely above about 35 to 40 mg/kg. Gyromitra mushrooms and hydrazine cause the same picture.

  • Situation Pyridoxine dose
  • Known amount 1 g IV for each gram of INH ingested (initial maximum 5 g)
  • Unknown amount, adult 5 g IV
  • Unknown amount, child 70 mg/kg IV (maximum 5 g)
  • Rate 0.5 to 1 g/min until seizures stop, then infuse the rest over 4 to 6 hours

Benzodiazepines act together with pyridoxine because both increase GABA activity. Phenytoin does not work for INH seizures. Pyridoxine injection is commonly supplied at 100 mg/mL, so a 5 g dose means 50 mL from many small vials. Stocking and a preparation plan are therefore pharmacy problems. If IV pyridoxine is unavailable, crushed tablets can be given by nasogastric tube.

Sulfonylureas: Octreotide

Glipizide, glyburide and glimepiride stimulate insulin release by closing pancreatic beta-cell potassium channels. A single tablet can cause serious hypoglycemia in a toddler. The onset may be delayed many hours with extended-release or long-acting products.

Why Dextrose Alone Fails

Dextrose corrects the glucose, but the rise in glucose triggers more sulfonylurea-driven insulin secretion. Patients then cycle through rebound hypoglycemia . Prophylactic dextrose in a well, normoglycemic child is not recommended because it can mask the onset of hypoglycemia.

Octreotide

Octreotide is a somatostatin analogue that blocks calcium entry into beta cells and stops insulin release.

Adults: 50 to 100 mcg SC or IV every 6 to 8 hours.

Children: about 1 to 1.5 mcg/kg SC or IV every 6 to 8 hours.

Continue while hypoglycemia recurs, then monitor glucose for at least 12 to 24 hours after the last dose .

Glucagon gives only a short rise and also stimulates insulin, so it is a bridge, not a treatment. Octreotide does not help an insulin overdose , because the insulin is exogenous; that patient needs dextrose and feeding.

Valproic Acid

Valproate overdose causes CNS depression, hyperammonemia (with or without liver injury), delayed cerebral edema, metabolic acidosis, hypernatremia, hypocalcemia and pancytopenia. Protein binding saturates at high concentrations, so the free fraction rises sharply.

L-carnitine: valproate depletes carnitine and impairs urea-cycle function. For hyperammonemia, hepatotoxicity or a large ingestion with CNS depression, give 100 mg/kg IV over 30 minutes (maximum 6 g) , then about 15 mg/kg IV every 4 hours until improvement.

Extracorporeal treatment (EXTRIP 2015): recommended for a valproate concentration above 1,300 mg/L , cerebral edema or shock. Suggested above 900 mg/L , with coma or respiratory depression requiring ventilation, acute hyperammonemia, or pH of 7.10 or lower. Intermittent hemodialysis is the preferred modality.

Carbapenems lower valproate concentrations by 60 to 100% within a day, so seizures can follow when the two are combined (Section 18.1).

Sympathomimetic Toxicity

Cocaine, amphetamines and synthetic cathinones cause agitation, tachycardia, hypertension, hyperthermia, seizures, rhabdomyolysis and acute coronary syndrome.

Benzodiazepines first: titrate diazepam, lorazepam or midazolam to control agitation, heart rate and blood pressure.

Temperature drives mortality: use ice-water immersion or aggressive evaporative cooling. Antipyretics do not work because the hypothalamic set point is normal. Severe hyperthermia may need intubation with a non-depolarizing paralytic.

Avoid succinylcholine in severe cases: rhabdomyolysis raises potassium, and plasma cholinesterase also metabolizes cocaine, so the two compete.

Persistent hypertension after sedation: phentolamine 1 to 5 mg IV, nitroglycerin or a calcium channel blocker. Beta-blockers are generally avoided during acute intoxication because of the theoretical risk of unopposed alpha stimulation; observational data are mixed.

Cocaine-associated chest pain: aspirin, benzodiazepines and nitroglycerin. A wide QRS from cocaine's sodium-channel blockade responds to sodium bicarbonate 1 to 2 mEq/kg, as in tricyclic toxicity (Section 9.1).

  • Local Anesthetic Systemic Toxicity (LAST)
  • Presentation

Early CNS signs are perioral numbness, metallic taste, tinnitus and agitation. These progress to seizures and coma. Cardiovascular toxicity starts with hypertension and tachycardia and then turns to bradycardia, QRS widening, ventricular dysrhythmias and asystole. Bupivacaine is the most cardiotoxic. Most cases begin within minutes, but toxicity can be delayed with continuous infusions or large-volume blocks.

Maximum Recommended Doses

The values below are commonly cited ceilings. Confirm them against product labeling and institutional policy, add up doses given at all sites, and use lower doses for older adults and for patients with heart or liver disease.

  • Agent Without epinephrine With epinephrine
  • Lidocaine 4.5 mg/kg (maximum 300 mg) 7 mg/kg (maximum 500 mg)
  • Bupivacaine 2.5 mg/kg (maximum 175 mg) 3 mg/kg (maximum 225 mg)
  • Ropivacaine 3 mg/kg Epinephrine adds little

Worked example: a 70-kg patient needs a laceration repair with plain 1% lidocaine (10 mg/mL). 4.5 mg/kg × 70 kg = 315 mg, which is capped at 300 mg. 300 mg ÷ 10 mg/mL = 30 mL maximum. With 1% lidocaine with epinephrine, 7 mg/kg × 70 kg = 490 mg, or 49 mL. For 0.25% bupivacaine (2.5 mg/mL), 175 mg is 70 mL.

Treatment (ASRA 2020 Checklist)

Stop the local anesthetic, call for help and ask for the LAST kit.

Give 100% oxygen and manage the airway; hypoxia and acidosis worsen toxicity.

Treat seizures with a benzodiazepine; avoid propofol if the patient is hemodynamically unstable.

Give 20% lipid emulsion:

Above 70 kg: 100 mL over 2 to 3 minutes , then 200 to 250 mL over 15 to 20 minutes.

70 kg or less: 1.5 mL/kg (lean body weight) over 2 to 3 minutes , then about 0.25 mL/kg/min.

If instability persists, repeat the bolus once or twice and double the infusion rate. The upper limit is about 12 mL/kg.

Modify ACLS: use small epinephrine doses (1 mcg/kg or less). Avoid vasopressin, calcium channel blockers, beta-blockers and other local anesthetics such as lidocaine or procainamide.

Arrange extracorporeal support early if the patient does not respond.

Monitor for at least 4 to 6 hours after a cardiovascular event and at least 2 hours after a limited CNS event.

Lipid emulsion interferes with many laboratory tests and can cause pancreatitis, so draw needed labs before large doses when possible.